• Featured Product
  • KD/KO Validated

Galc Polyclonal antibody

Galc Polyclonal Antibody for IHC, IP, WB, ELISA

Host / Isotype

Rabbit / IgG


human, mouse, rat and More (1)





Cat no : 11991-1-AP


2310068B06Rik, A930008M05Rik, AW212969, AW413532, Gacy, galactosylceramidase, Galc, twi, twitcher

Tested Applications

Positive WB detected inA375 cells, A549 cells, mouse brain tissue, rat brain tissue, SH-SY5Y cells
Positive IP detected inNIH/3T3 cells
Positive IHC detected inhuman gliomas tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB
Immunohistochemistry (IHC)IHC : 1:20-1:200
Sample-dependent, check data in validation data gallery

Product Information

11991-1-AP targets Galc in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman, mouse, zebrafish
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Galc fusion protein Ag3914
Full Name galactosylceramidase
Calculated molecular weight 77 kDa
Observed molecular weight 80 kDa, 30 kDa, 50 kDa
GenBank accession numberBC086671
Gene symbol Galc
Gene ID (NCBI) 14420
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

The GALC antibody targets the liposomal enzyme Galactosylceramidase (GALC), which belongs to the glycosyl hydrolase 59 family. It hydrolyzes the galactose ester bonds of galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. It is primarily found in the brain and kidneys where galactolipids are hydrolyzed (PMID:8634707). Deficiencies of GALC are primarily associated with the autosomal recessive Krabbe's disease. This disease is characterized by developmental delay caused by apoptosis of myelin-forming cells. GALC is responsible for hydrolyzing galactosylceramide, a cerebroside that is an important component of myelin. A deficiency in GALC causes loss of myelin to nerve cells, resulting in delayed nerve transmissions. Krabbe's disease has varying degrees of severity due to a large number of different genetic mutations in the gene. The GALC antibody can be used to detect the deletions in the GALC gene and functions of the enzyme (PMID:20886637). Normal GALC mRNA encodes the 80 kDa precursor, which is processed into 50 and 30 kDa subunits (PMID: 26865610).


Product Specific Protocols
WB protocol for Galc antibody 11991-1-APDownload protocol
IHC protocol for Galc antibody 11991-1-APDownload protocol
IP protocol for Galc antibody 11991-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Biochim Biophys Acta

Molecular cloning and knockdown of galactocerebrosidase in zebrafish: New insights into the pathogenesis of Krabbe's disease.

Authors - Daniela Zizioli
  • KO Validated

Glycoconj J

Impact of chronic kidney dysfunction on serum Sulfatides and its metabolic pathway in mice.

Authors - Yosuke Yamada

Cell Mol Biol (Noisy-le-grand)

Three-dimensional bio-printed constructs consisting of human umbilical-derived mesenchymal stem cells promote cell viability, proliferation, and differentiation in vitro.

Authors - Qingxia Tao

Oncol Rep

GALC gene is downregulated by promoter hypermethylation in Epstein-Barr virus-associated nasopharyngeal carcinoma.

Authors - Yinghai Zhao

J Mol Neurosci

Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis.

Authors - Jing-Wen Yu

Mol Genet Metab

Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.

Authors - Mohammad A Rafi